glp 1 alcohol addiction GLP-1s Hold Promise as Treatment for Use Disorder Exploring GLP-1 for Alcohol Addiction

Introduction Glucagon-like peptide-1 (GLP-1) receptor agonists, originally developed for the treatment of type 2 diabetes and obesity, have gained attention for their potential benefits beyond glucose regulation

To look at -cell production specifically, IL-6 injections were given twice daily for over a week and the protein content of pancreatic GLP-1 and insulin were both increased (60)

Table 1 and table 2 show the characteristics of the exposure groups before and after weighting

Abstract Background Glucagon-like peptide-1 (GLP-1) receptor agonists are important treatment options in obese patients with type 2 diabetes

This mechanism enhances glucose-dependent insulin secretion, suppresses inappropriately elevated glucagon secretion, and slows gastric emptying, which collectively improves glycemic control and promotes weight loss

Healthcare professionals and patients are encouraged to report any suspected adverse reactions through the Yellow Card Scheme (yellowcard